fda warning glp-1 october 2025 Alarming rise in weight loss drug overdoses GLP-1 RA Weight Loss Drugs

10.1016/s2215-0366(22)00317-0 113 SolisE.Jr.Cameron-BurrK

Considering the low rate of patient dropout (almost 12% in the L-carnitine group and 10% in the placebo group), to prevent a biased comparison, all analyses were performed on an ITT analysis dataset [29]

We found it surprising that there is relatively limited information available regarding the role that neuropeptides assume in regulating mucus secretion in asthma, COPD, and CF

Reasonable hypotheses with some mechanism behind them, but very little randomized evidence in healthy adults

This distinct mechanism underpins the rationale for combining Cagrilintide with GLP-1 therapies in investigational protocols such as CagriSema

Ill come back and edit this as I get more results (is editing the same post the best way to go about it?)